[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100557888":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":24,"centralContacts":29,"locations":24,"responsibleParty":39,"collaborators":24,"id":41,"slug":24,"hasResults":42,"nctId":43,"briefTitle":44,"officialTitle":45,"acronym":24,"eligibilityCriteria":46,"healthyVolunteers":42,"sex":47,"minAge":48,"maxAge":49,"enrollmentInfo":50,"targetDuration":24,"studyType":53,"phases":54,"briefSummary":56,"conditions":57,"keywords":24,"overallStatus":59,"whyStopped":24,"lastUpdateSubmitDate":60,"lastUpdatePostDateStruct":61,"startDateStruct":64,"completionDateStruct":66,"leadSponsor":68,"locationsCount":24},{"fullName":5,"class":6},"CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.","INDUSTRY",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Aprepitant Injection","EXPERIMENTAL","Before anesthesia induction, 4.4ml(32mg） was given by a single intravenous injection, which was completed within 30 seconds",[13],"Drug: Aprepitant Injection",{"label":15,"type":16,"description":17,"interventionNames":18},"Placebo","PLACEBO_COMPARATOR","Before anesthesia induction, 4.4ml(0mg）was given by a single intravenous injection, which was completed within 30 seconds",[19],"Drug: Aprepitant Injection Placebo",[21,25],{"type":22,"name":9,"description":11,"armGroupLabels":23,"otherNames":24},"DRUG",[9],null,{"type":22,"name":26,"description":27,"armGroupLabels":28,"otherNames":24},"Aprepitant Injection Placebo","Before anesthesia induction, 4.4ml(0mg） was given by a single intravenous injection, which was completed within 30 seconds",[15],[30,35],{"name":31,"role":32,"phone":33,"phoneExt":24,"email":34},"xiangdong chen, Doctor of Medicine(M.D.)","CONTACT","+86-027-85726300","xiangdongchen2013@163.com",{"name":36,"role":32,"phone":37,"phoneExt":24,"email":38},"Clinical Trials Information Group officer","86-0311-69085587","ctr-contact@cspc.cn",{"type":40,"investigatorFullName":24,"investigatorTitle":24,"investigatorAffiliation":24,"oldNameTitle":24,"oldOrganization":24},"SPONSOR","100557888",false,"NCT06543966","Efficacy and Safety Study of Aprepitant Injection for Prevention of Post-operative Nausea and Vomiting","A Randomized, Double-blind, Placebo-controlled, Multi-center Phase III Study to Evaluate the Efficacy and Safety of Aprepitant Injection in the Prevention of Post-operative Nausea and Vomiting","Inclusion Criteria:\n\nAge ≥18 and ≤75 years old; 18 \\\u003C BMI≤30kg\u002Fm\\^2, body weight ≥45kg; laparoscopic gynecologic or abdominal surgery under general anesthesia that was expected to last at least 1 hour.\n\nexpected or agreed to stay in the hospital for 24 hours or more after surgery;\n\nExclusion Criteria:\n\ndiagnostic surgery; scheduled for postoperative transfer to an intensive care unit; requiring placement of a nasogastric or orogastric tube after surgery; Post-operative vomiting may pose significant risk;","ALL","18 Years","75 Years",{"count":51,"type":52},486,"ESTIMATED","INTERVENTIONAL",[55],"PHASE3","A randomized, double-blind, placebo-controlled, multi-center phase III study to compare the efficacy and safety of aprepitant injection and placebo in the prevention of post-operative nausea and vomiting (PONV).,",[58],"Post-operative Nausea and Vomiting (PONV)","NOT_YET_RECRUITING","2024-08-05",{"date":62,"type":63},"2024-08-09","ACTUAL",{"date":65,"type":52},"2024-10-28",{"date":67,"type":52},"2026-03-28",{"name":5,"class":6}]